scholarly journals Endocrine aspects of anabolic steroids

1997 ◽  
Vol 43 (7) ◽  
pp. 1289-1292 ◽  
Author(s):  
F C W Wu
Keyword(s):  
Androgen Receptor ◽  
Anabolic Steroids ◽  
Muscle Size ◽  
Anabolic Action ◽  
Life Threatening ◽  
Disease Risks ◽  
Women And Children ◽  
Androgenic Anabolic Steroids ◽  
New Evidence

Abstract Understanding of the mechanism of androgen action has been enhanced by advances in knowledge on the molecular basis of activation of the androgen receptor and the importance of tissue conversion of circulating testosterone to dihydrotestosterone and estradiol. New evidence supports the view that supraphysiological doses of anabolic steroids do have a definite, positive effect on muscle size and muscle strength. However, the nature of the anabolic action of androgens on muscle is currently unclear and may involve mechanisms independent of the androgen receptor. The dose–response relationships of anabolic actions vs the potentially serious risks to health of androgenic-anabolic steroids (AAS) use are still unresolved. Most of the adverse effects of AAS are reversible but some are permanent, particularly in women and children. The reported incidence of acute life-threatening events associated with AAS abuse is low, but the actual risk may be underrecognized or underreported; the exact incidence is unknown. The long-term consequences and disease risks of AAS to the sports competitor remain to be properly evaluated.

THE EFFECT OF LONG-TERM ADMINISTRATION OF CORTISOL AND SOME ANDROGENIC-ANABOLIC STEROIDS ON THE RAT ADRENALS

1966 ◽  
Vol 51 (4) ◽  
pp. 481-487 ◽  
Author(s):  
O. Linèt ◽  
A. Bartovà
Keyword(s):  
Ascorbic Acid ◽  
Cholesterol Level ◽  
Anabolic Steroids ◽  
Corticosterone Level ◽  
Adrenal Weight ◽  
Daily Dose ◽  
Rat Adrenals ◽  
Term Administration ◽  
Androgenic Anabolic Steroids

ABSTRACT The effect of administration of some androgenic-anabolic steroids, as well as of cortisol and a combination of these steroids on the rat adrenals was investigated. 19-nortestosterone phenylpropionate (NTPP), methandrostenolone (MA) and dimethylandrostanolone (DMA) in a daily dose of 2 mg/100 g did not affect the adrenal weight and the corticosterone content, while the cholesterol level decreased. Cortisol 2 mg/100 g/day caused atrophy of this organ, accompanied by a marked reduction in cholesterol, ascorbic acid and corticosterone. NTPP or MA combined with cortisol caused an increase in adrenal weight, while cholesterol and corticosterone remained unchanged. DMA produced a similar effect except that it did not affect the adrenal atrophy caused by the administration of cortisol. An increase in the ascorbic acid level was observed in the group of animals receiving NTPP and cortisol as compared with the group treated with cortisol alone. 1,2α-oxido-androstane-3,17-dione, a compound without any androgenic-anabolic properties, but possessing some anticorticoid activity, given in a daily dose of 300 μg/100 g, normalized the cholesterol level in adrenals when combined with cortisol, but did not affect the decreased corticosterone level, caused by cortisol.

THE ACTION OF CORTICOSTEROIDS ON THE RENAL REABSORPTION OF CALCIUM

1960 ◽  
Vol XXXIV (I) ◽  
pp. 60-64 ◽  
Author(s):  
Helge Laake
Keyword(s):  
Anabolic Steroids ◽  
Tubular Reabsorption ◽  
Term Therapy ◽  
Renal Reabsorption ◽  
Endocrine Diseases ◽  
Anabolic Action ◽  
Small Doses ◽  
Long Term Therapy

ABSTRACT The tubular reabsorption of Ca has been studied by means of Ca clearance investigations in 16 patients with non endocrine diseases during long term therapy with small doses of corticosteroids. The tubular reabsorption of Ca was reduced in 7 patients. This is attributed to the anti-anabolic action of the corticosteroids on the cells of the tubules. Ca reabsorption became normal on administration of anabolic steroids.

scholarly journals Short QT interval is unreliable marker of anabolic androgenic steroid abuse in competitive athletes

2012 ◽  
Vol 140 (11-12) ◽  
pp. 711-716 ◽  
Author(s):  
Vitomir Djordjevic ◽  
Ivan Stankovic ◽  
Vlahovic Stipac ◽  
Biljana Putnikovic ◽  
Aleksandar Neskovic
Keyword(s):  
Qt Interval ◽  
Anabolic Steroids ◽  
Male Athletes ◽  
Steroid Abuse ◽  
Competitive Athletes ◽  
Androgenic Anabolic Steroids ◽  
Qt Interval Duration ◽  
Synthetic Derivatives ◽  
Derivatives Of

Introduction. Previous animal and human studies provided the evidence that testosterone may affect ventricular repolarization by shortening of the QT interval. Synthetic derivatives of testosterone, modified to enhance its anabolic properties, are occasionally abused by some competitive athletes. Objective. We assessed whether the QT interval duration could discriminate androgenic anabolic steroids (AAS)-using strength athletes (SA) from drug-free endurance athletes (EA), by comparing 25 formulas for QT interval correction. Methods. We recruited 22 elite male athletes involved in long-term strength or endurance training and 20 sedentary controls. All elite

Plasma Fibrinolytic Activity Following Oral Anabolic Steroid Therapy

1975 ◽  
Vol 34 (01) ◽  
pp. 236-245 ◽  
Author(s):  
I. D Walker ◽  
J. F Davidson ◽  
P Young ◽  
J. A Conkie
Keyword(s):  
Heart Disease ◽  
Ischaemic Heart Disease ◽  
Anabolic Steroid ◽  
Fibrinolytic Activity ◽  
Anabolic Steroids ◽  
Long Term Effects ◽  
Lysis Time ◽  
Detailed Evaluation ◽  
Euglobulin Lysis Time

SummarySix anabolic steroids were assessed for their ability to enhance plasma fibrinolytic activity in males with ischaemic heart disease. Five 17α-alkylated steroids (Ethyloestrenol, Norethandrolone, Methandienone, Methylandrostenediol and Oxymetholone) were examined and all produced a significant increase in plasma plasminogen activator as measured by the euglobulin lysis time. The only non-17α-alkylated steroid studied (Methenolone acetate) failed to enhance fibrinolysis. The 17α-alkylated steroids studied all deserve more detailed evaluation of their long term effects on plasma fibrinolytic activity.

scholarly journals Long-term outcomes after penile prosthesis placement for the Management of Erectile Dysfunction: a single-Centre experience

2021 ◽  
Vol 31 (1) ◽  
Author(s):  
Valentine Frydman ◽  
Ugo Pinar ◽  
Maher Abdessater ◽  
William Akakpo ◽  
Pietro Grande ◽  
...  
Keyword(s):  
Patient Satisfaction ◽  
Erectile Dysfunction ◽  
Penile Prosthesis ◽  
Perioperative Outcomes ◽  
Single Centre ◽  
Satisfactory Outcome ◽  
Single Centre Experience ◽  
Life Threatening ◽  
Few Data

Abstract Background Penile prothesis (PP) is the gold-standard treatment of drug-refractory erectile dysfunction (ED). While postoperative outcomes have been widely described in the literature, there are few data about patient satisfaction and intraoperative events. We aimed to assess long-term patient satisfaction and perioperative outcomes after PP implantation in a single-centre cohort of unselected patients using validated scales. Results A total of 130 patients received a PP (median age: 62.5 years [IQR: 58–69]; median International Index of Erectile Function (IEEF-5) score: 6 [IQR: 5–7]). Median follow-up was 6.3 years [IQR: 4–9.4]. Thirty-two (24.6%) patients underwent surgical revision, of which 20 were PP removals (15.4%). Global PP survival rate was 84.6% and previous PP placement was a risk factor for PP removal (p = 0.02). There were six (4.6%) non-life-threatening intraoperative events including two which resulted in non-placement of a PP (1.5%). EAUiaic grade was 0 for 124 procedures (95.4%), 1 for four procedures (3.1%) and 2 for two procedures (1.5%). Of patients who still had their PP at the end of the study, 91 (80.5%) expressed satisfaction. Conclusions PP implantation is a last-resort treatment for ED with a satisfactory outcome. PPs are well accepted by patients.

Sign in / Sign up

Export Citation Format

Share Document